News
14d
TipRanks on MSNVeru Implements 1-for-10 Reverse Stock Split
The latest announcement is out from Veru ( (VERU) ).
It's hard to set a price target for Veru stock - I doubt that the analysts' consensus price of $24 will be met unless Sabizabulin generates very impressive COVID data, and TADFIN is approved, but ...
Veru has a Strong Buy consensus rating, based on Buys only – 4, as it happens. According to the $15.75 average price target, there’s room for an additional 57% of upside over the next 12 months.
On Monday, Oppenheimer adjusted its price target for Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, reducing it to $5.00 from the previous $7.00.
The average Veru price target of $25 implies 103.5% upside potential.Analyst price targets range from a low of $21 per share to a high of $29 per share.A Stable Front from the Hedge FundsHedge ...
On Monday, Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ: VERU) shares, following the announcement of encouraging trial results.
Veru stock traded at a price of $2.5 in November 2020, but after the company released positive data from a Phase 2 study of Sabizabulin showing that the therapy had achieved a statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results